CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment
Bao S. Darvishi M. H Amin A. Al-Haideri M.T. Patra I. Kashikova K. Ahmad I. Alsaikhan F. Al-qaim Z.H. Al-Gazally M.E. Kiasari B.A. Tavakoli-Far B. Sidikov A.A. Mustafa Y.F. Akhavan-Sigari R.
August 2023Springer Science and Business Media Deutschland GmbH
Journal of Cancer Research and Clinical Oncology
2023#149Issue 107945 - 7968 pp.
CXC chemokine receptor type 4 (CXCR4) is a member of the G protein-coupled receptors (GPCRs) superfamily and is specific for CXC chemokine ligand 12 (CXCL12, also known as SDF-1), which makes CXCL12/CXCR4 axis. CXCR4 interacts with its ligand, triggering downstream signaling pathways that influence cell proliferation chemotaxis, migration, and gene expression. The interaction also regulates physiological processes, including hematopoiesis, organogenesis, and tissue repair. Multiple evidence revealed that CXCL12/CXCR4 axis is implicated in several pathways involved in carcinogenesis and plays a key role in tumor growth, survival, angiogenesis, metastasis, and therapeutic resistance. Several CXCR4-targeting compounds have been discovered and used for preclinical and clinical cancer therapy, most of which have shown promising anti-tumor activity. In this review, we summarized the physiological signaling of the CXCL12/CXCR4 axis and described the role of this axis in tumor progression, and focused on the potential therapeutic options and strategies to block CXCR4.
Cancer , CXCL12/CXCR4 axis , CXCR4 , CXCR4 blockers , Immunotherapy
Text of the article Перейти на текст статьи
The First Clinical Medical College, Xuzhou Medical University, Xuzhou, 221000, China
Infectious Diseases and Tropical Medicine Research Center (IDTMRC), Department of Aerospace and Subaquatic Medicine, AJA University of Medicinal Sciences, Tehran, Iran
Deanship of Scientific Research, Umm Al-Qura University, Makkah, 21955, Saudi Arabia
Zoology Department, Faculty of Science, Mansoura University, Mansoura, 35516, Egypt
Department of Physiotherapy, Cihan University-Erbil, Kurdistan Region, Erbil, Iraq
An Independent Researcher, National Institute of Technology Durgapur, West Bengal, Durgapur, India
Kazakh-Russian National Medical University, Almaty, Kazakhstan
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia
College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia
Department of Anesthesia Techniques, Al-Mustaqbal University College, Hillah, Iraq
College of Medicine, University of Al-Ameed, Karbala, Iraq
Virology Department, Faculty of Veterinary Medicine, The University of Tehran, Tehran, Iran
Dietary Supplements and Probiotic Research Center, Alborz University of Medical Sciences, Karaj, Iran
Department of Physiology and Pharmacology, Faculty of Medicine, Alborz University of Medical Sciences, Karaj, Iran
Rector, Ferghana Medical Institute of Public Health, Ferghana, Uzbekistan
Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, 41001, Iraq
Department of Neurosurgery, University Medical Center Tuebingen, Tübingen, Germany
Department of Health Care Management and Clinical Research, Collegium Humanum Warsaw Management University, Warsaw, Poland
The First Clinical Medical College
Infectious Diseases and Tropical Medicine Research Center (IDTMRC)
Deanship of Scientific Research
Zoology Department
Department of Physiotherapy
An Independent Researcher
Kazakh-Russian National Medical University
Department of Clinical Laboratory Sciences
College of Pharmacy
Department of Anesthesia Techniques
College of Medicine
Virology Department
Dietary Supplements and Probiotic Research Center
Department of Physiology and Pharmacology
Rector
Department of Pharmaceutical Chemistry
Department of Neurosurgery
Department of Health Care Management and Clinical Research
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026